Active surveillance and chemotherapy for germ cell tumors
Treatments studied
Part of Cancer clinical trials.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with a germ cell tumor, and the tumor type/stage must match the study’s low-risk or standard-risk groups
- You must have confirmed tumor diagnosis from tissue testing (biopsy or surgery pathology), with a few special marker-based exceptions
- Your age must fit the group: low-risk has no age limit; standard-risk is under 11 or 11–24 years old
- If you are in the standard-risk group (and will get chemotherapy), you must have blood counts and organ function that are strong enough for chemotherapy
- You must be healthy enough to tolerate treatment (activity level score can’t be too low)
- You must have never had chemotherapy or radiation for this current cancer (with limited exceptions for certain brain radiation in one group)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “molecular” (DNA-related) features of germ cell tumors in children and teens. It also follows patients over time, which can help researchers understand tumor patterns and improve future care.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
This phase 2 study looks at whether taking oral etoposide after high-dose chemotherapy helps people with a certain type of testicular or ovarian cancer avoid relapse. If you qualify, you may be assigned to take the medicine or simply be monitored without additional treatment.
This trial looks at tiny molecules in the blood to help diagnose ovarian germ cell tumors. It compares results from people with malignant (cancerous) tumors, benign (non-cancerous) tumors, and those without any gynecologic condition.
Hear when a new Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.